Ouster went public on the NYSE in March 2021 after it completed its business combination with Colonnade Acquisition Corp., a SPAC.
The Latest SPAC News and Rumors: September 21, 2022
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: Cano Health buys Doctor’s Medical Center for $300M, Ouster lays off 10% of staff, and Coeptis enters license agreement with University of Pittsburgh
Cano Health buys Doctor’s Medical Center for $300M to cement its primary care business in Florida
Miami-based Cano Health announced today the acquisition of fellow primary care provider Doctor’s Medical Center in a bid to grow its Medicare, Medicaid and Affordable Care Act (ACA) exchange memberships in South Florida.
The deal closed July 2 and ran Cano Health $300 million, $250 million of which the company said was financed by new debt.
Cano Health—which just recently joined the public markets through a $4.4 billion special purpose acquisition company merger—runs value-based primary care centers and provides support to other primary care practices treating senior patients.
Ouster lays off 10% of staff
Ouster (NYSE:OUST) announced that it is reducing its headcount by approximately 10%, reducing spending across the business by over 15% and suspending sales of common stock through at-the-market. The changes are part of the company’s comprehensive cost reduction initiative.
As of December 2021, Ouster employed approximately 217 people on a full-time basis in the U.S. and 61 people full-time internationally, for a total of 278 employees. Ousters cuts could affect around 28 employees in the company.
Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a “Multi-Antigen” CAR T Technology
Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer. Completion of the exclusive license agreement for SNAP-CAR follows Coeptis’ entry into an option agreement with the University of Pittsburgh announced in May 2022.
Bull Horn (NASDAQ:BHSE) entered into a definitive agreement to combine with biopharmaceutical company Coeptis in April.
READ